Development

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Articles

New approaches enable more patient-centric drug design that offers improved outcomes.

Emerging Technologies Advance Oral Drug Delivery

The Natoli AIM Data Acquisition and Analytical Software for Natoli’s NP-RD10A single-station tablet press speeds research and development.

Software Aids Product and Process Development for Pharmaceutical Tablets

Regis Cazes is strategic marketing director at Medelpharm, France, a company creating the STYL’One family of tableting instruments and providing contract lab services in powder characterization and tableting; rcazes@medelpharm.com.

Tableting instruments (i.e., compaction simulators) that simulate high-speed presses can be used in a quality-by-design (QbD) approach to perform in-depth material characterization and direct scale-up.

A QbD Approach to Shorten Tablet Development Time

Amjad Alhalaweh, PhD, is a formulation scientist at Recipharm.

The author discusses the advantages of high-throughput screening of drug formulation excipients by a fully automated Tecan-robotic system.

High Throughput Screening of Excipients

Peter Scholes is chief scientific officer at Quotient Sciences.

Integration of formulation development, real-time adaptive GMP manufacturing, and clinical testing using a consumer preference panel can save time and cost in performing taste-masking assessments.

Removing the Bitter Taste from Drug Development

Jan Vertommen is senior director, Product Development & Manufacturing, at Lonza.

Industry lessons from a fast-track technology transfer of a soft-gelatin capsule (softgel) are multifold. This case study reviews the success factors for effective execution of the technology transfer, which include: strong relationship between the customer, the contract development and manufacturing organization, and other partners based on deep knowledge in the technology; established and proven quality-by-design processes; risk mitigation management; project leadership; flawless execution; and mutual trust.

Case Study: Fast-Track Technology Transfer of a Soft-Gelatin Capsule

Abuse-deterrent opioid formulations generally fall into two categories: the first is based on a physiochemical abuse-deterrent approach and the second combines the opioid with an antagonist.

Tackling the Opioid Crisis with Abuse-Deterrent Formulations

Cycle and Aprecia will use Aprecia's 3DP Technology to improve rare disease drug formulations. 

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs

Orbis Biosciences’ Optimµm Platform delivers microparticulate dosage forms with controlled-release and taste-masked properties in a single manufacturing step. 

Manufacturing Microparticles in a Single Step

Softgel capsules are a popular dosage form among patients but they also provide a number of manufacturing benefits over liquid-filled hardgel capsules.

Formulation and Drug Delivery, Solid Dosage